TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 35nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 35nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 59nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 68nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 150nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair